Fortune India’s latest issue dives into Biocon’s future-focused strategy, as founder Kiran Mazumdar-Shaw outlines a well-defined succession plan to ensure seamless leadership continuity and sustained growth. In a detailed interaction, she shares her vision for future-proofing the company she built. Meanwhile, in another significant development, Dilip Shanghvi makes a bold global move with Sun Pharma’s $11.75 billion acquisition of Organon, strengthening its position in women’s health and biosimilars. The issue also captures the surge of over $70 billion in investments transforming India’s rapidly expanding data centre ecosystem, with major conglomerates and global tech giants competing for scale and dominance.
FORTUNE INDIA — AN RP-SANJIV GOENKA GROUP PUBLICATION.
Fortune is one of the most respected business magazines in the world. It is known for its unrivaled access to world’s most influential leaders and decision-makers. In a world of business long on information and short on time, Fortune stands out with trusted insight, deep reporting and provocative story telling. Few publications cover the world of business with as much depth, breadth, wisdom, and panache. That’s why Fortune is recognized as ‘the best magazine in the world that just happens to be about business’. Fortune 500 is perhaps the best-known brand in business journalism and the ultimate hallmark of corporate success. Launched in India in October 2010, Fortune India retains the spirit of the global brand with respect to thought leadership and practice from across the world every month while adding an Indian dimension. It is the only truly global business magazine dedicated to the global success of Indian business leaders, offering actionable insights to propel their businesses. Fortune Indai is published every month. Fortune India publishes 12 issues (10-regular issues and 2 special- 500 listing issues) in a year. Single Issue Digital price for regular issues is 200 INR and 300 INR for special issues
